JP2007504229A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504229A5 JP2007504229A5 JP2006525369A JP2006525369A JP2007504229A5 JP 2007504229 A5 JP2007504229 A5 JP 2007504229A5 JP 2006525369 A JP2006525369 A JP 2006525369A JP 2006525369 A JP2006525369 A JP 2006525369A JP 2007504229 A5 JP2007504229 A5 JP 2007504229A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- treating
- preventing
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000000304 alkynyl group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 208000019901 Anxiety disease Diseases 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000017164 Chronobiology disease Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 2
- 230000027288 circadian rhythm Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 229910052757 nitrogen Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 208000027753 pain disease Diseases 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 0 CCOc1c(Nc2cccc(C)n2)ncc(*)c1 Chemical compound CCOc1c(Nc2cccc(C)n2)ncc(*)c1 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49962703P | 2003-09-02 | 2003-09-02 | |
| PCT/US2004/027916 WO2005021529A1 (en) | 2003-09-02 | 2004-08-27 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007504229A JP2007504229A (ja) | 2007-03-01 |
| JP2007504229A5 true JP2007504229A5 (enExample) | 2007-07-05 |
Family
ID=34272848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525369A Withdrawn JP2007504229A (ja) | 2003-09-02 | 2004-08-27 | 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070027321A1 (enExample) |
| EP (1) | EP1664018A1 (enExample) |
| JP (1) | JP2007504229A (enExample) |
| CN (1) | CN1845915A (enExample) |
| AU (1) | AU2004268112A1 (enExample) |
| CA (1) | CA2537141A1 (enExample) |
| WO (1) | WO2005021529A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1458383B1 (en) * | 2001-12-18 | 2007-11-21 | Merck & Co., Inc. | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| JP4493341B2 (ja) * | 2002-03-12 | 2010-06-30 | メルク・シャープ・エンド・ドーム・コーポレイション | 代謝型グルタメート受容体−５の二アリール置換テトラゾールモジュレータ |
| US20060194807A1 (en) * | 2003-04-03 | 2006-08-31 | Cosford Nicholas D P | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| EP1613615A2 (en) * | 2003-04-03 | 2006-01-11 | Merck & Co., Inc. | 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5 |
| CN101384568B (zh) * | 2006-02-15 | 2012-12-12 | 雅培制药有限公司 | 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 |
| CN101415683B (zh) | 2006-03-31 | 2013-07-17 | 诺瓦提斯公司 | 新化合物 |
| WO2008155588A1 (en) * | 2007-06-18 | 2008-12-24 | Richter Gedeon Nyrt. | Sulfonyl-quinoline derivatives |
| SI2209778T1 (sl) | 2007-09-21 | 2012-12-31 | Array Biopharma, Inc. | Piridin-2-il-amino-I, 2,4-tiadiazol derivati kot aktivatorji glukokinaze za zdravljenje sladkorne bolezni |
| AU2008310097B2 (en) | 2007-10-09 | 2013-05-16 | Merck Patent Gmbh | Pyridine derivatives useful as glucokinase activators |
| US7800382B2 (en) | 2007-12-19 | 2010-09-21 | AEHR Test Ststems | System for testing an integrated circuit of a device and its method of use |
| WO2009130900A1 (ja) * | 2008-04-24 | 2009-10-29 | 日本曹達株式会社 | オキシム誘導体、中間体化合物および植物病害防除剤 |
| WO2010077992A1 (en) * | 2008-12-17 | 2010-07-08 | Amgen Inc. | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors |
| US8030957B2 (en) | 2009-03-25 | 2011-10-04 | Aehr Test Systems | System for testing an integrated circuit of a device and its method of use |
| JPWO2012121314A1 (ja) * | 2011-03-09 | 2014-07-17 | 第一三共株式会社 | ジピリジルアミン誘導体 |
| CN103619170B (zh) | 2011-05-04 | 2016-07-06 | 默沙东公司 | 含有氨基-吡啶的脾酪氨酸激酶(syk)抑制剂 |
| WO2013081094A1 (ja) * | 2011-11-30 | 2013-06-06 | 東レ株式会社 | イミダゾ［１，２－ａ］ピリジン誘導体及びその医薬用途 |
| JP6267193B2 (ja) * | 2012-05-22 | 2018-01-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 置換ジピリジルアミン類及びそれらの使用 |
| JP2014196274A (ja) * | 2013-03-29 | 2014-10-16 | 三井化学株式会社 | 多環芳香族炭化水素の誘導体の製造方法 |
| KR102288542B1 (ko) * | 2014-12-24 | 2021-08-11 | 삼성에스디아이 주식회사 | 웨어러블 기기의 무선 충전 장치 및 시스템 |
| US10543212B2 (en) | 2017-03-27 | 2020-01-28 | Cardurion Pharmaceuticals, Llc | Substituted amines for treating cardiac diseases |
| JP7569688B2 (ja) * | 2017-12-22 | 2024-10-18 | ハイバーセル，インコーポレイテッド | ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体 |
| MX2021003516A (es) | 2018-09-25 | 2021-05-27 | Cardurion Pharmaceuticals Llc | Compuesto de aminopirimidina. |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| WO2021089300A1 (en) * | 2019-11-05 | 2021-05-14 | Thulin Claes | 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4h-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of surmenage in a mammal |
| WO2021143729A1 (zh) * | 2020-01-15 | 2021-07-22 | 中国科学院上海药物研究所 | 多靶点抑制作用化合物、组合物、功能分子及其应用 |
| PE20240148A1 (es) | 2020-09-28 | 2024-02-06 | Cardurion Pharmaceuticals Inc | COMPUESTOS DE HETEROARILO FUSIONADO Y SU USO COMO INHIBIDORES DE CaMKII |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE422799B (sv) * | 1975-05-28 | 1982-03-29 | Merck & Co Inc | Analogiforfarande for framstellning av 1,3-dihydroimidazo (4,5-b)pyridin-2-oner |
| EP0837367B1 (en) * | 1996-10-16 | 2002-04-10 | Sumitomo Chemical Company Limited | Positive resist composition comprising a dipyridyl compound |
| US6180650B1 (en) * | 1999-04-23 | 2001-01-30 | Merck Frosst Canada & Co. | Heterosubstituted pyridine derivatives as PDE 4 inhibitors |
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| JP2004502692A (ja) * | 2000-07-04 | 2004-01-29 | ニューロサーチ、アクティーゼルスカブ | アリール及びヘテロアリールジアザビシクロアルカン類、その製造方法及びその使用方法 |
| AU2002341921B2 (en) * | 2001-10-04 | 2007-05-31 | Merck Sharp & Dohme Corp. | Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| CA2468067A1 (en) * | 2001-11-30 | 2003-06-12 | Merck & Co., Inc. | Metabotropic glutamate receptor-5 modulators |
| EP1458383B1 (en) * | 2001-12-18 | 2007-11-21 | Merck & Co., Inc. | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| AU2002366388B2 (en) * | 2001-12-18 | 2008-09-18 | Merck & Co., Inc. | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| AU2002364906B2 (en) * | 2001-12-21 | 2007-08-16 | Merck & Co., Inc. | Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
| JP4493341B2 (ja) * | 2002-03-12 | 2010-06-30 | メルク・シャープ・エンド・ドーム・コーポレイション | 代謝型グルタメート受容体−５の二アリール置換テトラゾールモジュレータ |
| EP1613615A2 (en) * | 2003-04-03 | 2006-01-11 | Merck & Co., Inc. | 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5 |
| US20060194807A1 (en) * | 2003-04-03 | 2006-08-31 | Cosford Nicholas D P | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| AU2004227833B2 (en) * | 2003-04-04 | 2009-10-01 | Merck & Co., Inc. | Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| CA2425817A1 (en) * | 2003-04-17 | 2004-10-17 | Queen's University At Kingston | Organic luminescent compounds and methods of making and using same |
| US20060189661A1 (en) * | 2003-11-03 | 2006-08-24 | Wagenen Bradford V | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| EP1715867A4 (en) * | 2004-02-12 | 2009-04-15 | Merck & Co Inc | BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 |
-
2004
- 2004-08-27 JP JP2006525369A patent/JP2007504229A/ja not_active Withdrawn
- 2004-08-27 US US10/570,068 patent/US20070027321A1/en not_active Abandoned
- 2004-08-27 CN CNA2004800250675A patent/CN1845915A/zh active Pending
- 2004-08-27 CA CA002537141A patent/CA2537141A1/en not_active Abandoned
- 2004-08-27 EP EP04782403A patent/EP1664018A1/en not_active Withdrawn
- 2004-08-27 WO PCT/US2004/027916 patent/WO2005021529A1/en not_active Ceased
- 2004-08-27 AU AU2004268112A patent/AU2004268112A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007504229A5 (enExample) | ||
| TWI338684B (en) | Tetrahydroquinoline derivatives and a process for preparing the same | |
| JP5442717B2 (ja) | 二置換フタラジンヘッジホッグ経路アンタゴニスト | |
| CN107108631B (zh) | 作为蛋白激酶抑制剂的6-氨基-7-二环-7-脱氮-嘌呤衍生物 | |
| TW444013B (en) | Quinoline and quinazoline compounds useful in treating benign prostatic hyperplasia | |
| KR102093608B1 (ko) | 이미다조피리딘 화합물 | |
| US8993594B2 (en) | Isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors | |
| JP4216196B2 (ja) | Ｎｐｙアンタゴニストとしてのキノリン誘導体 | |
| JP2007523152A5 (enExample) | ||
| JP2005518414A5 (enExample) | ||
| CA2389306A1 (en) | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | |
| JP2007511504A5 (enExample) | ||
| JP6380777B2 (ja) | ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物 | |
| JP2006507355A5 (enExample) | ||
| JP2008513516A5 (enExample) | ||
| JP2009536161A5 (enExample) | ||
| JPWO2000039116A1 (ja) | アミノピラゾール誘導体 | |
| WO2001062738A1 (en) | Novel imidazoline compounds | |
| JP2013509392A5 (enExample) | ||
| JP2010501478A5 (enExample) | ||
| JP2004507527A5 (enExample) | ||
| IE67288B1 (en) | 1-indolyalkyl-4-(alkoxypyrimidinyl) piperazines | |
| JP2008505107A5 (enExample) | ||
| JP2004532823A5 (enExample) | ||
| JP2010506919A5 (enExample) |